This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

Up With Corticotropin-Releasing Factor, Down With Acetylcholine

Arch Gen Psychiatry. 1999;56:991-992.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE PAST decade has witnessed remarkable advances in molecular neurobiology, and they have been increasingly applied to the study of the pathophysiology of neuropsychiatric disease. Perhaps no disease has been scrutinized more intensely than Alzheimer disease (AD) in this regard, and 2 recent comprehensive reviews have highlighted these advances.^1-2 The sheer number of individuals with AD renders it a public health problem of major magnitude; more than 4 million persons in the United States are believed to be afflicted with this neurodegenerative disorder, most in their 70s, 80s, and 90s. The cost to society is extraordinary, with estimates as high as $60 billion annually.

Every medical student now knows that AD was first described by the German psychiatrist who gave the disease its name in the early 1900s at the Max Planck Institute for Psychiatry in Munich. I have had the pleasure of viewing his original slides there, arranged by . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Neuropeptide Abnormalities in Patients With Early Alzheimer Disease
Kenneth L. Davis, Richard C. Mohs, Deborah B. Marin, Dushyant P. Purohit, Daniel P. Perl, Melinda Lantz, Gregory Austin, and Vahram Haroutunian
Arch Gen Psychiatry. 1999;56(11):981-987.
ABSTRACT | FULL TEXT